Dietary approach to managing mild-to-moderate psoriasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of dietary interventions, specifically focusing on gluten sensitivity, in patients with mild-to-moderate psoriasis. It aims to explore the gut-skin axis and how dietary changes may influence the inflammatory processes associated with psoriasis. Participants will undergo an open wheat challenge and a placebo challenge to assess their reactions and symptoms. The study seeks to understand the potential link between diet and psoriasis severity, particularly in patients who may have gluten sensitivity.

Why it matters

Who can join: the full rules

Inclusion criteria of psoriasis patients

* age \>18 and \<65 years;
* no systemic therapy for psoriasis for at least 3 months before inclusion in the study;
* negativity of anti-deamidated gliadin protein (anti-DGP) immunoglobulins (Ig) class A (IgA) and immunoglobulins (Ig)G, anti-tissue transglutaminase (anti-tTG) class IgA and IgG, and Endomysium antibodies (EmA);
* absence of WA (negative prick-test and/or specific serum immunoglobulins (Ig)E assay for wheat, gluten, and gliadin).

Exclusion criteria of psoriasis patients age \<18 and \>65 years;

* severe chronic plaque-type psoriasis (based on BSA);
* self-exclusion of gluten/wheat from the diet and refusal to reintroduce it, for diagnostic purposes, before entering the study;
* pregnancy;
* alcohol and/or drug abuse;
* Helicobacter pylori and other bacterial and/or parasitic infections;
* diagnosis of chronic inflammatory bowel disease and other organic pathology affecting the digestive system (e.g., severe liver disease), nervous system diseases, major psychiatric disorders, immunological deficits, and impairments that limit physical activity;
* diagnosis of cancer
* treatment with steroids and/or immunological therapies;
* patients undergoing chemotherapy and/or radiotherapy.

Where it's running

• Dermatology Department of the University Hospital 'P. Giaccone' of Palermo, Italy,
  Palermo, Palermo, Italy Recruiting
• Internal Medicine Department of the University Hospital of Palermo
  Palermo, Palermo, Italy Recruiting
• Internal Medicine Division of the "Cervello-Villa Sofia" Hospital
  Palermo, PA, Italy Recruiting

Study contacts

• Study coordinator: Pasquale Mansueto, MD
• Email: pasquale.mansueto@unipa.it
• Phone: +393477279879

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HB0017 Injection safety and PK in low-weight adults at different injection sites

  This early-phase study tests a single subcutaneous HB0017 injection in healthy, low-weight adults and compares how the body processes the drug when injected at different sites.

  Recruiting Phase 1 Huabo Biopharm Co., Ltd. · Hangzhou, Zhejiang · NCT07920861

• MK-8644: first-in-human test in healthy people and people with psoriasis

  This early-phase study tests MK-8644 versus placebo in healthy volunteers and people with psoriasis to see if it is safe and tolerable.

  Recruiting Phase 1 Merck Sharp & Dohme LLC · Melbourne, Victoria · NCT07850310

• Is XJH05 Ointment Effective for Plaque Psoriasis?

  This study tests whether the XJH05 ointment can help people with plaque psoriasis compare to a calcipotriol ointment.

  Recruiting Xijing Hospital · Xi'an, Shaanxi · NCT07780929

• Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care

  This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.

  Recruiting Janssen-Cilag Kft. · Budapest · NCT07746583

• TQH3906 capsules vs warmer options in adults with moderate to severe plaque psoriasis

  This Phase 3 trial tests whether once-daily TQH3906 capsules can help adults with moderate to severe plaque psoriasis better than a placebo or the active drug deucravacitinib.

  Recruiting at 13 sites Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 44 other locations · NCT07724366

• SHR-1139 injectable treatment for adults with plaque psoriasis

  This study tests whether an SHR-1139 injection works and is safe for adults with plaque psoriasis.

  Recruiting Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Guangzhou, Guangzhou · NCT07719530

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.